Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.
It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. Main risk factors contributing to DSPN are smoking, obesity, hyperlipidemia, duration of diabetes, large total exposure to hyperglycemia, advanced age, elevated lipid levels, elevated blood pressure, kidney disease, cigarette smoking, overweight, increased height, and others.
DelveInsight launched a new report on Diabetic Peripheral Neuropathy Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report– The total diagnosed prevalent population of Diabetic Peripheral Neuropathy in 7MM was 25,332,829 in 2017.– Among all the countries, the US has higher Diabetic Peripheral Neuropathy prevalent population of 12,522,483 cases in 2017.– Among the EU5 countries in 2017, Germany had the highest prevalent cases of Diabetic Peripheral Neuropathy of 3,904,730 cases.
Download report @https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market
Key benefits of the report1. Diabetic Peripheral Neuropathy market report covers a descriptive overview and comprehensive insight of the Diabetic Peripheral Neuropathy epidemiology and Diabetic Peripheral Neuropathy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Diabetic Peripheral Neuropathy market report provides insights on the current and emerging therapies.
3. Diabetic Peripheral Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Diabetic Peripheral Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diabetic Peripheral Neuropathy market.
“Diabetic Peripheral Neuropathy Market Size in the 7MM was USD 2,275.52 million in 2017.”
The current Diabetic Peripheral Neuropathy medications are antidepressants, anticonvulsants, topical agents and opioids.
Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group. The medications can be chosen according to patient comorbidities, side effects, drug interaction, and cost.
Three treatments are currently approved by both FDA and EMA for pain associated with Diabetic Peripheral Neuropathy —pregabalin, duloxetine, and extended-release tapentadol. However, no treatments have been approved for the prevention or reversal of Diabetic Peripheral Neuropathy.
Request for sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market
The launch of the emerging therapies is expected to significantly impact Diabetic Peripheral Neuropathy treatment scenario in the upcoming years:-Drugs covered1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others
The key players in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Gruenenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others
Table of contents1. Key Insights2. Executive summary3. Diabetic Peripheral Neuropathy Market Overview at a Glance4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology5. Diabetic Peripheral Neuropathy Disease Background and Overview6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population6.1. Key Findings6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM6.3. United States6.4. EU56.5. Germany6.6. France6.7. Italy6.8. Spain6.9. United Kingdom (UK)6.10. Japan7. Diabetic Peripheral Neuropathy Treatment and Management8. Unmet need9. Diabetic Peripheral Neuropathy Marketed Drugs9.1. Key cross competition9.2. Qutenza: Gruenenthal9.3. Tarlige: Daiichi Sankyo10. Diabetic Peripheral Neuropathy Emerging drugs10.1. Key cross competition10.2. VM202: Helixmith10.3. NYX-2925: Aptinyx10.4. WST-057: WinSanTor10.5. Ricolinostat: Regenacy Pharmaceuticals10.6. Cebranopadol: Gruenenthal10.7. ISC 17536: Ichnos Science10.8. NRD135S.E1: Novaremed10.9. MEDI7352: AstraZeneca10.10. Trazodone/Gabapentin: Angelini11. Diabetic Peripheral Neuropathy Market Size11.1. Key Findings11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM11.3. Market Outlook: 7 MM11.4. United States11.5. EU511.6. Germany11.7. France11.8. Italy11.9. Spain11.10. United Kingdom11.11. Japan12. Reimbursement policies13. Market Drivers14. Market Barriers15. SWOT Analysis16. KOL Views17. Case Report18. A Case Report of DPN19. Bibliography20. Appendix21. Diabetic Peripheral Neuropathy Report Methodology22. DelveInsight Capabilities23. Disclaimer24. About DelveInsight
Download sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/